Background: Although anti-IgE antibody (Ab) therapy was recently shown to be effective in patients with bronchial asthma, no study has reported the effect of IgE therapy in the prevention of wasp venom anaphylaxis. In this study, we used a mouse model of wasp venom allergy to investigate the effect of anti-IgE Ab on wasp venom anaphylaxis.
Introduction
Immediate-type allergic reactions are represented by allergic rhinitis and conjunctivitis, bronchial asthma, atopic dermatitis, and reactions triggered by drugs, food, wasp venom, and latex. Among them, allergic reactions due to drug, food, wasp venom, and latex are mediated by immunoglobulin (Ig) E and are associated with a variety of symptoms. Upon exposure to an antigen (Ag), chemical messengers such as histamine and serotonin are released IgE-dependently from mast cells and basophils in the skin, the conjunctiva, the mucosa of the oral cavity, nose, and airway, and the lining of the digestive tract. In addition, within 30 min of allergen exposure, bronchial smooth muscle contraction, dilated blood vessels, and increased vascular permeability develop because of the synthesis and secretion of lipid mediators, including leukotriene (LT) B4, LTC4, and prostaglandin (PG), due to activation of arachidonic acid, a cell membrane lipid. On the other hand, development of symptoms associated with allergic retinitis, bronchial asthma, and atopic dermatitis requires the presence of local chronic allergic inflammation mediated mostly by T cells in addition to IgEdependent reactions. Therefore, different pathological mechanisms are likely to exist, even within IgEdependent immediate-type allergies.
To understand such pathology, different mouse models of IgE-dependent immediate-type allergy have been developed using allergens such as ovalbumin (OVA), 1 mite Ag (Der p2), 2 Aspergillus fumigatus extract, 3 cedar pollen, 4 latex Ag (Hev b5), 5 wheat (gliadin), 6 and penicillin. 7 However, almost no studies have investigated the pathogenesis of wasp venom allergy in detail using an mouse model.
Recently, therapy targeting IgE has been established, and its efficacy towards bronchial asthma, 8 pollinosis, 9 and food allergy 10 has been shown in mice and humans. However, the effect of anti-IgE therapy in wasp venom allergy has remained unreported. Therefore, we developed a mouse model of wasp venom allergy using a wasp venom extract as an allergen to elucidate the pathogenesis of wasp venom allergy and the efficacy of anti-IgE antibody (Ab).
Methods

Animals
Female 6-week-old BALB/c mice were purchased from Japan SLC (Hamamatsu, Japan) and maintained under specific pathogen-free conditions. The Animal Ethics Committee of Dokkyo University School of Medicine approved all in vivo manipulations.
Sensitization of mice with wasp venom
Wasp venom (10 µg, 20 µg/ml, 0.5 ml/mouse; Hollister-Stier Laboratories, Spokane, WA) adsorbed in 5 mg aluminum hydroxide gel (aluminium potassium sulfate (Alum); 20 mg/ml, 0.25 ml/mouse; Wako Pure Chemical Industries, Osaka, Japan) was intraperitoneally (i.p.) injected into BALB/c mice to develop a mouse model of wasp venom allergy (Figure 1a ). Another group of mice were injected with a vehicle (0.25 ml adjuvant + 0.25 ml physiological saline/mouse) as nonsensitized controls. Mice injected with wasp venom were further divided into 5 groups based on the number of immunizations: once on experimental day (day) 0 (one-sensitization group), twice on days 0 and 7 (two-sensitization group), 3 times on days 0, 7, and 14 (three-sensitization group), 4 times on days 0, 7, 14, and 21 (four-sensitization group), and 5 times on days 0, 7, 14, 21, and 28 (fivesensitization group). Five mice were used in each experimental and control group. Wasp venom challenge was performed via i.p. injection of 10 µg of wasp venom (20 µg/ml, 0.5 ml/mouse) 14 days after the last immunization in each group. Rectal temperature was measured before and after wasp venom challenge using a digital thermometer (OMRON Corporation, Kyoto, Japan). Blood was collected through the tail vein immediately before challenge and from the aorta (1 ml) using a syringe immediately after cervical dislocation following challenge. Blood was centrifuged at 3000 rpm for 10 min at 4 °C to separate the serum which was subsequently stored at −80 °C until measurement of total IgE, LTB4, and LTC4 levels.
Expression of cytokine in spleen cell cultures
The spleen was removed from mice sensitized twice with wasp venom and aluminum adjuvant on days 0 and 7 to culture splenocytes in RPMI1640 medium (Sigma-Aldrich, St. Louis, MO) + 10% FCS (Sigma-Aldrich). Cells (1 × 10 6 cells/ml) were not stimulated, stimulated non-specifically with anti-CD3 Ab (10 µg/ml; Ancell Corporation, Bayport, MN) + anti-CD28 Ab (1 µg/ml; Becton Dickinson Biosciences, Franklin Lakes, NJ), or stimulated specifically with wasp venom (10 µg/ml). The mRNA levels of interleukin (IL)-4, IL-5, IL-13, and interferon-gamma (IFN-γ) were measured using (a) BALB/c mice were immunized via i.p. injection of wasp venom + aluminium potassium sulfate (Alum); 20 mg/ml, 0.25 ml/mouse; (10 µg+ 5 mg, respectively/mouse; sensitization group) or Alum + saline (5 mg + 0.25 ml, respectively/mouse; non-sensitized group). Mice were further divided into five groups sensitized 1 to 5 times in interval of one weeks. Wasp venom challenge (10 µg/mouse) was performed via i.p. injection 2 weeks after the last immunization in each group. Total IgE Ab levels in the serum were measured before challenge, and body temperature (B.T.) and the levels of LTB4 and LTC4 were measured before and 30 min after challenge. (b) On day 21, the spleen was removed from mice immunized twice on day 0 and 7 with wasp venom and Alum to establish splenocyte culture cells. Cells were stimulated with or without anti-CD3 Ab + anti-CD28 Ab or specifically with wasp venom. Both mRNA and protein levels of IL-4, 5, 13, and IFN-γ were determined by real-time PCR or by ELISA after stimulation, respectively. (c) Mice sensitized twice with wasp venom were divided into the sensitized and non-sensitized group. On day 20, mice were Ag-specifically treated with mouse anti-IgE Ab or non-specifically with rat anti-IgG1κ isotype Ab. Another group of mice did not receive Ab as a control. All groups were challenged with wasp venom on day 21, and B.T, total IgE levels in the serum before challenge, and LTC4 levels were measured before and 30 min after challenge. Five mice were used in each experimental and control group. i.p.: intraperitoneally.
real-time PCR 8 h after stimulation, and their protein levels in culture medium supernatant were determined by the enzyme linked immunosorbent assay (ELISA) 24 h after stimulation (Figure 1b) .
Expression of cytokine mRNA in splenocytes
At each time point, splenocyte culture supernatants were removed, washed with PBS, and stored at −80 °C for a few days. Splenocyte culture supernatants were thawed at 0 °C in 1 mL of TRIzol reagent, a monophasic solution of phenol and guanidine isothiocyanate (Invitrogen, Carlsbad, CA), then homogenized using a microhomogenizer (10 000 × g, 90 s). Total RNA was extracted by the modified guanidine isothiocyanate-phenol-chloroform method, as recommended by the manufacturer. Total RNA (5 µg) was immediately reverse-transcribed using Superscript III reverse transcriptase (Invitrogen) and oligo(dT) primers (Amersham Pharmacia Biotech, Piscataway, NJ) as recommended by the manufacturers. The resultant cDNA products were diluted in Tris-EDTA buffer and used for real-time quantitative PCR.
Real-time quantitative PCR
Quantification of cytokine mRNA expression was performed by real-time RT-PCR. PCR was performed on an ABI/PRISM 7000 sequence detection system and analyzed using ABI/PRISM 7000 SDS v1.0 software (Applied Biosystems, Foster City, CA). β-Actin was used as an internal control. PCR conditions were as follows: 4 µL of cDNA was mixed with 12.5 µL of Power SYBR Green PCR Master Mix (Applied Biosystems) and 1.5 µL of primer mix (15 pmol) and adjusted to a final volume of 25 µL. The thermal cycler conditions were as per the manufacturer's instructions. Standard curves for cytokine mRNA were generated using cDNA from the splenocyte of naïve BALB/c mice. Amplification of standard cDNA and sample cDNA was carried out in 96-well reaction plates. Each plate contained the same standard cDNA. Cycling conditions included a hot start at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, and 60 °C for 1 min. Accumulation of product was monitored by SYBR green fluorescence. The data from two runs were averaged and relative expression levels were determined from a standard curve of serial dilutions of cDNA samples. Cytokine mRNA levels were expressed as absolute numbers of copies, after normalization to β-actin mRNA levels. The primers for real-time quantitative RT-PCR were as follows: mouse β-actin, 5′-CCAGCCTTCCTTCTTGGGTAT (forward), 5′-TGGCATAGAGGTCTTTACGGATGT (reverse). Mouse IL-4, IL-5, IL-13 and interferon (IFN)-γ primers were obtained from Takara Bio (Madison, WI).
Measurement of total IgE in mice serum
Concentrations of total IgE in serum were measured using ELISA kits (YAMASA Corporation, Tokyo, Japan). The sensitivity of each assay exceeded 10 ng/mL.
Measurement of chemical mediators and cytokines in splenocyte culture supernatants
Concentrations of LTB 4, LTC 4 (Cayman, Ann Arbor, MI) in splenocyte culture supernatants were assessed by enzyme immunoassay, which had sensitivities of >3.9 and 7.8, respectively. Concentrations of IL-4, IL-5, IL-13, and IFN-γ in splenocyte culture supernatants were measured using ELISA kits (R&D Systems, Minneapolis, MN). The sensitivity of each assay exceeded 7.8, 15.6, 7.8, and 9.4 pg/mL, respectively.
Anti-IgE Ab
Mice sensitized twice with wasp venom were divided into two groups: a sensitized group (n=5) and non-sensitized group (n=5). On day 20, mice were pretreated with mouse anti-IgE Ab (1 µg/mouse; Becton Dickinson Bioscience) that recognizes the Igh-C(a) and Igh-C(b) haplotypes. Controls received rat anti-IgG1κ isotype Ab (1 µg/mouse; Becton Dickinson Bioscience). On day 21, wasp venom challenge was performed via i.p. injection, and body temperature and the levels of total IgE and LTC4 in the serum were measured 30 min after challenge (Figure 1c ) by the method described above.
Statistical analysis
Data are expressed as mean ± SD values. Statistical significance between groups was assessed by the Student's t-test, at the same time point if the data were normally distributed. An overall significance level of 0.05 was used for all statistical comparisons. 
Results
Change
Change of serum IgE level by immunization of wasp venom
Two weeks after the last immunization with wasp venom, the total serum IgE levels were 17.5±26.0 pg/ml in the two-sensitization group, 36.7±16.6 pg/ml in the three-sensitization group, and 121.6±31.2 pg/ml in the five-sensitization group, demonstrating that the levels were higher with increasing number of immunizations.
Levels of serum LTB 4 and LTC 4 by venom challenge
The serum levels of LTB4 and LTC4 were determined 30 min after wasp venom challenge in the two-sensitization group. Although LTB4 levels barely changed between before (8.7±3.3 nM) and after (11.7±6.3 nM) challenge, wasp venom challenge significantly increased the level of LTC4 from 52.4±11.0 to 124.0±28.4 pg/ml (p <0.05). Even after challenge, LTB4 and LTC4 were undetectable in the non-sensitized group.
Expression of cytokine mRNA and protein in splenocytes by stimulation with αCD3 and αCD28 or wasp venom
To elucidate the patterns of cytokine production in the wasp venom allergy model, the expression of IL-4, IL-5, IL-13, and IFN-γ in splenocytes due to Ag-specific stimulation was studied at the mRNA (Figure 3a ) and protein (Figure 3b) 
Effects of anti IgE Ab on serum total IgE level
We investigated the effect of anti-IgE Ab on serum total IgE levels ( Figure 4 ). While the level was 105.9±23.1 pg/ml in the mouse model of wasp venom allergy, the levels were 42.2±15.9 and 112.1±23.4 pg/ml in mice treated with anti-IgE and anti-IgG1 Ab, respectively, demonstrating that the administration of anti-IgE Ab significantly inhibited the rise in the serum total IgE levels.
Effects of body temperature by anti IgE Ab
We then measured body temperature to reveal the effect of anti-IgE Ab on anaphylactic reactions in the mouse model ( Figure 5 ).
Wasp venom challenge did not significantly change the body temperature of mice treated with anti-IgG1 Ab (37.7±0.1 to 37.1±0.3 °C). In mice treated with anti-IgE Ab, the temperature did not change between before and after challenge (37.8±0.2 and 37.8±0.2 °C). These results show that the administration of anti-IgE Ab significantly inhibited the drop in body temperature compared with mice not treated with the Ab (p <0.05).
Effects of serum LTC4 levels by anti IgE Ab
We also investigated the effect of anti-IgE Ab on the serum levels of LTC4 in the mouse model ( Figure 6 ). In mice not treated with Ab and in those (1 × 10 6 cells/ml) derived from mice in the non-sensitized group and those sensitized twice on days 0 and 7 were stimulated with 10 µg/ml anti-CD3 Ab + 1 µg/ml anti-CD28 Ab or 10 µg/ml wasp venom. The mRNA levels of cytokines were determined 8 h after stimulation. (b) Splenocytes were prepared and stimulated as described above, and the levels of IL-4, 5, 13, and IFN-γ in the supernatant were determined using ELISA 24 h after stimulation. White and black bars represent nonsensitized mice (control) and sensitized mice (mice model), respectively. Data are expressed as mean ± SD values for each group. Significance was set at p <0.05 for comparison without wasp venom or with nonsensitized mice. N.S.: not significant; N.D.: not detected. 
Discussion
Anti-IgE Ab has demonstrated its effectiveness against asthma 8 , allergic rhinitis 9 , and food allergy 10 in humans and in animal models. Here we show for the first time that anti-IgE Ab suppresses the onset of anaphylaxis. However, the efficacy of anti-IgE Ab on wasp venom anaphylaxis in humans requires further investigation.
Histamine 11 and serotonin released from mast cells and basophils play an important role in the pathology of anaphylaxis, and mediators such as LTB4, 12 LTC4, 13 and PG 14 are also known to be involved in the mechanism. To elucidate the pathology of anaphylaxis, various mouse models have been developed using OVA, 1 chemical substance (hapten TNP), 15 wheat-dependent exercise- induced anaphylaxis (gliadin), 16 and antimicrobial agent (penicillin G). 7 Anaphylactic reactions in mice are reportedly mediated by two pathways: an IgEdependent pathway with IgE-mast cells as the major player 16 and another pathway mediated by IgG1 with macrophages and basophils as the major players. 17 In this study, while body temperature decreased significantly in the one-to three-sensitization groups, the reduction was increasingly inhibited as the number of immunizations increased beyond four. These results suggest that, although mice were fully sensitized after one to three immunizations, hyposensitization resulted from more than four immunizations, presumably because of the depletion of histamine and the production of blocking Ab (wasp venom-specific IgG4). 18 We then investigated how the number of immunizations affects the production of IgE. A previous study reported the use of an aluminum adjuvant and recombinant major wasp venom allergen to successfully produce specific IgE Ab in the mouse model. 19 In the present mouse model, we also used an aluminum adjuvant to sensitize mice with wasp venom, and we observed a production of total IgE Ab a in the previous study. 19 IgE was detectable after the second immunization, and the production increased with increasing number of immunizations after the third immunization. These results suggest that the production of IgE Ab was dependent on wasp venom allergen. Histamine is frequently used as an indicator of mediators in IgE-dependent immediate-type anaphylaxis. However, we could not accurately assess the level of histamine in the present study because histamine was detected as a non-specific reaction due to the high histamine content of wasp venom. We therefore used LTB4 and LTC4 secreted from neutrophils and basophils or from eosinophils, respectively, as indicators to measure the pre-and post-challenge levels of total IgE in mice sensitized twice. While the levels of LTB4 did not change after wasp venom challenge, LTC4 levels increased significantly. LTB4 production due to the stimulation of platelet-activating factor (PAF) is reportedly involved in the pathogenesis of anaphylaxis, and intravenous injection of PAF is known to attenuate anaphylactic reaction in an inflammatory model using mice deficient in leukotriene B4 receptor 1 (BLT1), a receptor for LTB4. 20 However, the involvement of LTB4 in anaphylactic reactions was not clear in the present study. Because LTC4 is also known to be produced via an IgE-dependent pathway in fooddependent aspirin-induced anaphylaxis, 21 LTC4 elevation seen after wasp venom challenge in this study likely plays a role in the pathogenesis of wasp venom-associated anaphylaxis.
When elucidating the patterns of Th cytokine production in our mouse model in response to splenocyte culture cells, we observed that the Agspecific stimulation did not change the expression of IFN-γ, but rather, it significantly upregulated the Th2 cytokines IL-4, IL-5, and IL-13, suggesting the involvement of Th2 type responses in our wasp venom allergy model. We also detected elevated levels of IL-4 in the controls after non-specific stimulation with αCD3. A previous study reported that even in the naïve Th state against foreign Ag, Th2 responses are preferentially induced in BALB/c mice compared with other mouse strains, 22 and this might have been the cause of the high levels of IL-4 after non-specific stimulation in the present study.
In recent years, a number of studies have reported the development of anti-IgE Ab, including omalizumab, in several allergic diseases 9, [23] [24] [25] , including asthma 8 and food allergy 10 . By binding to the secreted form of human IgE Igh-C (c) (Cε3), omalizumab inhibits the interaction between IgE and high-affinity immunoglobulin E receptor (FcεR1) present on the surface of mast cells and basophils. The drug also attenuates IgE-dependent immediateand delayed-type allergic reactions in humans through the inhibition of histamine release 26 and the production of chemical mediators, such as leukotriene, 27 reduction of free IgE, 28 down-regulation of FcεR1, 29 and suppression of Th2 cytokine induction. 30 At the same time, many studies have investigated the use of mouse anti-IgE Ab in mouse models of allergic diseases, such as chronic asthma induced with OVA. 31 These studies reported IgE Ab-dependent attenuation of allergic reactions, including a reduction in total IgE, 31 inhibition of Th2 cytokine induction, 31 and inhibition of histamine release. 32 To reveal the efficacy of anti-IgE Ab in our mouse model of wasp venom anaphylaxis, we pretreated the mice with anti-IgE Ab that recognizes the Igh-C (a) and Igh-C (b) haplotypes or with anti-IgG1 Ab prior to the measurement of body temperature and total IgE Ab levels. We observed increased levels of total IgE Ab in the serum and decreased body temperature in mice treated with anti-IgG1 Ab and controls. On the other hand, inhibition of total IgE upregulation and prevention of a body temperature drop were observed in mice treated with anti-IgE Ab. We also measured the serum levels of LTC4 to investigate the effect of the Ab on chemical mediators. While no changes in the levels of LTC4 were detected in the controls or mice treated with anti-IgG1 Ab, the expression of LTC4 was significantly inhibited in mice treated with anti-IgE Ab. The anti-mouse IgE Ab used in the present study reacts with the Igh-C(a) and (b) haplotypes and is thus capable of binding to free and membrane bound IgE. It is therefore likely that the Ab functioned as a neutralizing Ab by binding to free IgE and competitively inhibiting their interaction with FcεR1 on mast cells and basophils. The Ab might have also inhibited the cross-linking of wasp venom allergens to membrane-bound IgE by binding to the latter.
The results of the present study suggest that an IgE-dependent pathway plays a major role in the onset of anaphylaxis in the mouse model of wasp venom allergy. It is therefore possible that anaphylactic reactions following exposure to the allergen can be blocked by the administration of anti-IgE Ab. Specific immunotherapy for wasp venom anaphylaxis has been established, 33 and its efficacy and safety have been shown in clinical settings. Similarly, the present study showed that anti-IgE Ab can be an effective tool for preventing wasp venom-induced anaphylaxis. While anti-IgE Ab directly inhibits the activity of IgE Ab, specific immunotherapy is thought to exert its effects indirectly by increasing the production of IgEspecific IgG Ab that acts as a blocking Ab. Immunotherapy is generally effective; however, even patients who undergo immunotherapy for five consecutive years are known to have an anaphylaxis recurrence rate of 10-15% after discontinuation 34 . Anti-IgE Ab is also believed to be effective during treatment, but because its inhibitory effect is temporary, anaphylaxis is expected to recur after discontinuation. In addition, although the costeffectiveness of immunotherapy has recently been reported 35 , it is difficult to compare the economic impacts of immunotherapy with anti-IgE Ab because each country handles health insurance and medical practice differently. Furthermore, despite the cost of anti-IgE Ab therapy not being covered by health insurance in Japan, the use of anti-IgE Ab is recommended during seasons known for frequent Hymenoptera stings and in posts-immunotherapy patients as well as immunotherapy patients with severe anaphylactic reactions.
In summary, we developed a mouse model of wasp venom allergy and investigated the pathology of anaphylaxis and the efficacy of anti-IgE Ab on such reactions. The results demonstrate that an IgEdependent pathway(s) play a primary role in the anaphylactic onset caused by wasp venom and that the administration of anti-IgE Ab can prevents the onset. These findings suggest the potential clinical application of anti-IgE Ab therapy in humans.
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